skip to content

Other

Abbott sales up

29 January 2015 13:13

Abbott Laboratories saw fourth-quarter worldwide sales rise to $5.4bn from continuing operations - an increase of 10.2% on an operational basis, including double-digit growth in emerging markets.

Worldwide sales increased 5.6% on a reported basis, including an unfavourable 4.6% effect of foreign exchange.

Abbott reports diluted earnings per share, excluding specified items, of $0.71 in the fourth quarter and $2.28 for the full year, above its previous guidance range and reflecting 13.4% growth. This includes results from both continuing and discontinued operations. Reported diluted EPS under GAAP was $0.59 in the fourth quarter and $1.49 for the full year.

EPS guidance for continuing operations, excluding specified items, for thjis year is $2.10 to $2.20. Projected full-year 2015 EPS for continuing operations under GAAP is $1.33 to $1.43.

Chairman and chief executive Miles D. White said: "We ended 2014 with good momentum, well positioned for a step-up in operational sales growth in 2015.

"While we'll need to manage through currency headwinds again in 2015, we're targeting another year of top-tier earnings growth."

Story provided by StockMarketWire.com

Related Company: ABT

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?

aew-banner-180x255.jpg -

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.